Wolinsky-Friedland M
Associated Internists of Danbury, Connecticut, USA.
Endocrinol Metab Clin North Am. 1995 Jun;24(2):395-420.
Drug-induced metabolic bone disease via modification of resorption, formation, and mineralization is responsible for a spectrum of disorders classified as osteoporosis, osteomalacia, and adynamic bone disease. Bone disease and the coincident risk of fracture and disability are well-documented with use of glucocorticoids, L-thyroxine, ethanol, tobacco, anticonvulsants, neuroleptics, and chemotherapeutic agents. Physician awareness of these risks highlights the need for close monitoring of dosages and drug interactions and allows for intervention with nutritional support, antiresorptive agents, and proformation agents.
通过改变骨吸收、骨形成和矿化而导致的药物性代谢性骨病，可引发一系列被归类为骨质疏松症、骨软化症和骨无动力症的疾病。使用糖皮质激素、左甲状腺素、乙醇、烟草、抗惊厥药、抗精神病药和化疗药物时，骨病以及随之而来的骨折和残疾风险已有充分记录。医生对这些风险的认识凸显了密切监测剂量和药物相互作用的必要性，并允许通过营养支持、抗吸收药物和促形成药物进行干预。
